🇺🇸 FDA
Pipeline program

CM-101

CM-101-SC-001

Phase 1 small_molecule completed

Quick answer

CM-101 for Nonalcoholic Steatohepatitis (NASH) is a Phase 1 program (small_molecule) at Chemomab Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Chemomab Therapeutics
Indication
Nonalcoholic Steatohepatitis (NASH)
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials